Analyst Comments: Qiagen, Virgin Media, Priceline, NovaMed

Qiagen Spending for Growth Qiagen N.V. (QGEN), through its subsidiaries in Europe, Asia, Australia, Canada, and the U.S., operates in the life sciences industry with a portfolio of more than 500 products and automated solutions. Though the molecular diagnostic and research market offer enormous growth, the company faces stiff competition. As such, we maintain our Hold rating for Qiagen. The company continues to remain aggressive on the acquisition front. The most significant deal closed by the company in July 2007, is the acquisition of Digene Corp., which should boost the topline going forward. Another recent significant acquisition was Corbett Life Sciences which occurred in July 2008. We believe the company will continue entering into strategic partnerships and alliances going forward. We are optimistic on a number of new... [read full story]